Seilern Investment Management Ltd Sells 10,499 Shares of Edwards Lifesciences Corporation $EW

Seilern Investment Management Ltd lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 589,732 shares of the medical research company’s stock after selling 10,499 shares during the period. Edwards Lifesciences makes up 6.4% of Seilern Investment Management Ltd’s portfolio, making the stock its 5th biggest position. Seilern Investment Management Ltd owned approximately 0.10% of Edwards Lifesciences worth $50,906,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Pin Oak Investment Advisors Inc. bought a new stake in shares of Edwards Lifesciences in the second quarter valued at about $26,000. TrinityBridge Ltd bought a new position in shares of Edwards Lifesciences during the second quarter worth about $27,000. GK Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at approximately $26,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $26,000. Finally, Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences during the 1st quarter worth approximately $25,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the topic of several research analyst reports. Citigroup reissued a “buy” rating on shares of Edwards Lifesciences in a report on Monday, October 5th. Truist Financial increased their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. BTIG Research reissued a “buy” rating and issued a $110.00 price objective on shares of Edwards Lifesciences in a report on Friday, September 11th. Finally, Royal Bank Of Canada raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $85.65, for a total value of $53,017.35. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,428,912.10. The trade was a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,045 shares of company stock valued at $451,596 over the last three months. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Down 0.9%

Shares of NYSE EW traded down $0.77 during trading on Tuesday, hitting $85.62. 964,470 shares of the company traded hands, compared to its average volume of 4,496,346. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The business’s fifty day moving average is $88.67 and its 200 day moving average is $86.22. The firm has a market capitalization of $49.30 billion, a price-to-earnings ratio of 49.24, a P/E/G ratio of 2.23 and a beta of 0.87. Edwards Lifesciences Corporation has a fifty-two week low of $72.40 and a fifty-two week high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the company posted $0.67 EPS. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.